Drug
Pemigatinib clinical trials
Also written INCB054828 and Pemazyre.
- studies test it
- 46
- open now
- 20
- in phase 3
- 1
- first study started
- 2016
Keep track of what changes. Save the pemigatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2022 (9)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 9 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 39
- Phase 3
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 32
Incyte Corporation (11) · Academic and Community Cancer Research United (2) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · University of Utah (1) · Fondazione per la Medicina Personalizzata (1) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
Vemurafenib (4) · Cobimetinib (4) · Alectinib (4) · Entrectinib (4) · Atezolizumab (4) · Durvalumab (4) · Erlotinib (3) · Trastuzumab (3)
Studies
Open first, then newest update. How each study uses pemigatinib is read from its arms, and is right about nine times in ten.
Testing it · 46
- A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic TherapyNot yet recruitingPhase 2Incyte CorporationNCT07862998Written as Pemigatinib
- A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementRecruitingPhase 2Mehmet AkceNCT06728410Written as Pemigatinib
- Pemigatinib + Afatinib in Advanced Refractory Solid TumorsRecruitingPhase 1Massachusetts General HospitalNCT06302621Written as Pemigatinib
- Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaRecruitingPhase 2Ohio State University Comprehensive Cancer CenterNCT07780838Written as Pemigatinib
- A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)RecruitingPhase 2Lund University HospitalNCT06389799Written as Pemigatinib
- Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 FusionRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06439485Written as Pemigatinib
- Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid LeukemiaRecruitingPhase 1OHSU Knight Cancer InstituteNCT04659616Written as Pemigatinib
- PH 2 Pemigatinib in SDH-deficient GISTRecruitingPhase 2Dana-Farber Cancer InstituteNCT07434843Written as Pemigatinib
- A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic AlterationsRecruitingPhase 2Sameek RoychowdhuryNCT06906562Written as Pemigatinib
- Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor CellsRecruitingPhase 2UNICANCERNCT06653777Written as Pemigatinib
- Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid TumorNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06551896Written as Pemigatinib
- Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract CarcinomaNot yet recruitingPhase 2Eastern Hepatobiliary Surgery HospitalNCT06530823Written as Pemigatinib and Durvalumab
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Pemigatinib
- Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerRecruitingPhase 2The Fourth Affiliated Hospital of Zhejiang University School of MedicineNCT05004974Written as Pemigatinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Pemigatinib
- Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid TumorsRecruitingPhase 2Tianjin Medical University Second HospitalNCT06022289Written as Pemigatinib
- A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR VariantNot yet recruitingPhase 2Sun Yat-sen UniversityNCT05997459Written as Pemigatinib
- Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 AlterationsRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT05651672Written as Pemigatinib
- A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR AlterationsRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT05560334Written as Pemigatinib Pill
- A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard TherapyRecruitingPhase 2Zhejiang Cancer HospitalNCT05559775Written as Pemigatinib Pill
See all 46 studies that test pemigatinib →
Given in every arm · 3 — pemigatinib is usual care beside what is tested
- Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.CompletedPhase 2Incyte CorporationNCT04463771Written as pemigatinib
- The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.TerminatedPhase 2Incyte CorporationNCT04949191Written as Pemigatinib
- Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)TerminatedPhase 1/2Incyte CorporationNCT02393248Written as Pemigatinib
Codes
What other systems call pemigatinib · ClinicalTrials.gg INT001280
- MeSH (NLM) C000705477pemigatinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Y6BX7BL23KPEMIGATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2359268One source FDA
- Wikidata Q96398739pemigatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C121553PemigatinibOne source FDA
- DrugBank DB15102One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705477 | pemigatinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Y6BX7BL23K | PEMIGATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2359268 | — | One source FDA |
| Wikidata | Q96398739 | pemigatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C121553 | Pemigatinib | One source FDA |
| DrugBank | DB15102 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.